{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:51:11Z","timestamp":1793987471320,"version":"4.8.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019492","name":"National Natural Science Foundation of China-China Academy of General Technology Joint Fund for Basic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Developing influenza vaccines that protect against a broad range of viruses is a global health priority. Several conserved viral proteins or domains have been identified as promising targets for such vaccine development. However, none of the targets is sufficiently immunogenic to elicit complete protection, and vaccine platforms that can enhance immunogenicity and deliver multiple antigens are desperately needed. Here, we report proof-of-concept studies for the development of next-generation influenza vaccines using the bacteriophage T4 virus-like particle (VLP) platform. Using the extracellular domain of influenza matrix protein 2 (M2e) as a readout, we demonstrate that up to ~1,281 M2e molecules can be assembled on a 120 x 86 nanometer phage capsid to generate M2e-T4 VLPs. These M2e-decorated nanoparticles, without any adjuvant, are highly immunogenic, stimulate robust humoral as well as cellular immune responses, and conferred complete protection against lethal influenza virus challenge. Potentially, additional conserved antigens could be incorporated into the M2e-T4 VLPs and mass-produced in\n                    <jats:italic>E. coli<\/jats:italic>\n                    in a short amount of time to deal with an emerging influenza pandemic.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.745625","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T13:48:09Z","timestamp":1634132889000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development"],"prefix":"10.3389","volume":"12","author":[{"given":"Mengling","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengju","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanpo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venigalla B.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2018.11.005","article-title":"Broadly Protective Influenza Vaccines: Design and Production Platforms","volume":"34","author":"Elbahesh","year":"2019","journal-title":"Curr Opin Virol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz803","article-title":"Lessons From Influenza Pandemics of the Last 100 Years","volume":"70","author":"Monto","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00344","article-title":"The Quest for a Truly Universal Influenza Vaccine","volume":"9","author":"Jang","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12985-017-0918-y","article-title":"Towards a Universal Influenza Vaccine: Different Approaches for One Goal","volume":"15","author":"Sautto","year":"2018","journal-title":"Virol J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.1900022","article-title":"Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice","volume":"3","author":"Choi","year":"2019","journal-title":"ImmunoHorizons"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/v6083159","article-title":"Options and Obstacles for Designing a Universal Influenza Vaccine","volume":"6","author":"Jang","year":"2014","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.15","article-title":"A Chimeric Haemagglutinin-Based Influenza Split Virion Vaccine Adjuvanted With AS03 Induces Protective Stalk-Reactive Antibodies in Mice","volume":"1","author":"Nachbagauer","year":"2016","journal-title":"NPJ Vaccines"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and New Influenza Vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/vaccines7040169","article-title":"Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins","volume":"7","author":"Jazayeri","year":"2019","journal-title":"Vaccines"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1909613116","article-title":"Future Epidemiological and Economic Impacts of Universal Influenza Vaccines","volume":"116","author":"Sah","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12462","article-title":"Continuing Challenges in Influenza","volume":"1323","author":"Webster","year":"2014","journal-title":"Ann New Y Acad Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-Generation Influenza Vaccines: Opportunities and Challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-med-120611-145115","article-title":"Toward a Universal Influenza Virus Vaccine: Prospects and Challenges","volume":"64","author":"Pica","year":"2013","journal-title":"Annu Rev Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-120617-041310","article-title":"Is a Universal Influenza Virus Vaccine Possible","volume":"71","author":"Nachbagauer","year":"2020","journal-title":"Annu Rev Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2017.11.018","article-title":"A Novel Peptide-Based Vaccine Candidate With Protective Efficacy Against Influenza A in a Mouse Model","volume":"515","author":"Herrera-Rodriguez","year":"2018","journal-title":"Virology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e01534-18","DOI":"10.1128\/JVI.01534-18","article-title":"Why Are CD8 T Cell Epitopes of Human Influenza A Virus Conserved","volume":"93","author":"Li","year":"2019","journal-title":"J Virol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41541-020-0174-9","article-title":"Efficacy of FLU-V, a Broad-Spectrum Influenza Vaccine, in a Randomized Phase IIb Human Influenza Challenge Study","volume":"5","author":"Pleguezuelos","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2015.10.003","article-title":"The Quest for a Universal Flu Vaccine: Headless HA 2.0","volume":"18","author":"Krammer","year":"2015","journal-title":"Cell Host Microbe"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.07.005","article-title":"Correlates of Protection Against Influenza Infection in Humans\u2013on the Path to a Universal Vaccine","volume":"25","author":"Li","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/vaccines9070698","article-title":"Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted With ALFQ Induce Broadly Neutralizing Antibodies","volume":"9","author":"Sei","year":"2021","journal-title":"Vaccines"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.11.6644-6654.2005","article-title":"Influenza Type A Virus Escape Mutants Emerge In Vivo in the Presence of Antibodies to the Ectodomain of Matrix Protein 2","volume":"79","author":"Zharikova","year":"2005","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41467-017-02725-4","article-title":"Double-Layered Protein Nanoparticles Induce Broad Protection Against Divergent Influenza A Viruses","volume":"9","author":"Deng","year":"2018","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.007","article-title":"M2e-Based Universal Influenza A Vaccine","volume":"27","author":"Fiers","year":"2009","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1115352","article-title":"Strategies Towards Universal Pandemic Influenza Vaccines","volume":"15","author":"He","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e59081","DOI":"10.1371\/journal.pone.0059081","article-title":"M2e-Displaying Virus-Like Particles With Associated RNA Promote T Helper 1 Type Adaptive Immunity Against Influenza A","volume":"8","author":"Iba\u00f1ez","year":"2013","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1003495","DOI":"10.1371\/journal.ppat.1003495","article-title":"Mutated and Bacteriophage T4 Nanoparticle Arrayed F1-V Immunogens From Yersinia Pestis as Next Generation Plague Vaccines","volume":"9","author":"Tao","year":"2013","journal-title":"PLoS Pathog"},{"key":"B27","doi-asserted-by":"publisher","first-page":":e01926-18","DOI":"10.1128\/mBio.01926-18","article-title":"A Bacteriophage T4 Nanoparticle-Based Dual Vaccine Against Anthrax and Plague","volume":"9","author":"Tao","year":"2018","journal-title":"mBio"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.024","article-title":"Vaccine Options for Influenza: Thinking Small","volume":"53","author":"Schepens","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/vaccines6040066","article-title":"Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity Against Influenza Virus","volume":"6","author":"Kim","year":"2018","journal-title":"Vaccines"},{"key":"B30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.antiviral.2017.01.021","article-title":"Consensus M2e Peptide Conjugated to Gold Nanoparticles Confers Protection Against H1N1, H3N2 and H5N1 Influenza A Viruses","volume":"141","author":"Tao","year":"2017","journal-title":"Antiviral Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/13484","article-title":"A Universal Influenza A Vaccine Based on the Extracellular Domain of the M2 Protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1472-6750-11-106","article-title":"Efficient Production of Chimeric Human Papillomavirus 16 L1 Protein Bearing the M2e Influenza Epitope in Nicotiana Benthamiana Plants","volume":"11","author":"Mati\u0107","year":"2011","journal-title":"BMC Biotechnol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990337","article-title":"Immunogenicity and Protective Efficacy of Candidate Universal Influenza A Nanovaccines Produced in Plants by Tobacco Mosaic Virus-Based Vectors","volume":"19","author":"Petukhova","year":"2013","journal-title":"Curr Pharm Des"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e45765","DOI":"10.1371\/journal.pone.0045765","article-title":"Immunization With M2e-Displaying T7 Bacteriophage Nanoparticles Protects Against Influenza A Virus Challenge","volume":"7","author":"Hashemi","year":"2012","journal-title":"PLoS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.06.010","article-title":"Multiple Heterologous M2 Extracellular Domains Presented on Virus-Like Particles Confer Broader and Stronger M2 Immunity Than Live Influenza A Virus Infection","volume":"99","author":"Kim","year":"2013","journal-title":"Antiviral Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.05.028","article-title":"High Epitope Density in a Single Recombinant Protein Molecule of the Extracellular Domain of Influenza A Virus M2 Protein Significantly Enhances Protective Immunity","volume":"23","author":"Liu","year":"2004","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.07.020","article-title":"The Density Code for the Development of a Vaccine","volume":"105","author":"Cheng","year":"2016","journal-title":"J Pharm Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.addr.2018.06.025","article-title":"Bacteriophage T4 Nanoparticles for Vaccine Delivery Against Infectious Diseases","volume":"145","author":"Tao","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0126650","DOI":"10.1371\/journal.pone.0126650","article-title":"Protection Against Influenza A Virus Challenge With M2e-Displaying Filamentous Escherichia Coli Phages","volume":"10","author":"Deng","year":"2015","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1300867110","article-title":"In Vitro and In Vivo Delivery of Genes and Proteins Using the Bacteriophage T4 DNA Packaging Machine","volume":"110","author":"Tao","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1021\/acssynbio.7b00179","article-title":"Engineering of Bacteriophage T4 Genome Using CRISPR-Cas9","volume":"6","author":"Tao","year":"2017","journal-title":"ACS Synth Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00235-06","article-title":"Assembly of Human Immunodeficiency Virus (HIV) Antigens on Bacteriophage T4: A Novel in vitro Approach to Construct Multicomponent HIV Vaccines","volume":"80","author":"Sathaliyawala","year":"2006","journal-title":"J Virol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.10.010","article-title":"Multicomponent Anthrax Toxin Display and Delivery Using Bacteriophage T4","volume":"25","author":"Shivachandra","year":"2007","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6869-5_15","article-title":"Bacteriophage T4 as a Nanoparticle Platform to Display and Deliver Pathogen Antigens: Construction of an Effective Anthrax Vaccine","volume":"1581","author":"Tao","year":"2017","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00440","article-title":"Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine","volume":"10","author":"Boudreau","year":"2019","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"7639","DOI":"10.1038\/s41598-017-07372-9","article-title":"The Anti-Influenza M2e Antibody Response Is Promoted by XCR1 Targeting in Pig Skin","volume":"7","author":"Deloizy","year":"2017","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.32607\/20758251-2019-11-4-22-32","article-title":"Non-Neutralizing Antibodies Directed at Conservative Influenza Antigens","volume":"11","author":"Sedova","year":"2019","journal-title":"Acta Naturae"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1703207","DOI":"10.1002\/smll.201703207","article-title":"Intranasal Nanovaccine Confers Homo- and Hetero-Subtypic Influenza Protection","volume":"14","author":"Qi","year":"2018","journal-title":"Small (Weinheim an der Bergstrasse Germany)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2017.14","article-title":"M2e-Tetramer-Specific Memory CD4 T Cells Are Broadly Protective Against Influenza Infection","volume":"11","author":"Eliasson","year":"2018","journal-title":"Mucosal Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12929-019-0572-3","article-title":"M2e-Based Universal Influenza Vaccines: A Historical Overview and New Approaches to Development","volume":"26","author":"Mezhenskaya","year":"2019","journal-title":"J BioMed Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1093\/infdis\/jiz003","article-title":"The Role of Matrix Protein 2 Ectodomain in the Development of Universal Influenza Vaccines","volume":"219","author":"Saelens","year":"2019","journal-title":"J Infect Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2015.01060","article-title":"High Copy Numbers and N Terminal Insertion Position of Influenza A M2E Fused With Hepatitis B Core Antigen Enhanced Immunogenicity","volume":"9","author":"Sun","year":"2015","journal-title":"Biosci Trends"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00226","article-title":"Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines","volume":"8","author":"Gomes","year":"2017","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00795-004-0255-2","article-title":"Immunoinflammatory Responses and Fibrogenesis","volume":"37","author":"Azouz","year":"2004","journal-title":"Med Electron Microsc"},{"key":"B55","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/bmj.321.7258.424","article-title":"Th1 and Th2 Responses: What are They","volume":"321","author":"Berger","year":"2000","journal-title":"BMJ (Clin Res ed)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"118050","DOI":"10.1016\/j.carbpol.2021.118050","article-title":"Immunostimulatory Effect of Chitosan and Quaternary Chitosan: A Review of Potential Vaccine Adjuvants","volume":"264","author":"Li","year":"2021","journal-title":"Carbohydr Polymers"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01457","article-title":"Influenza and Antibody-Dependent Cellular Cytotoxicity","volume":"10","author":"Von Holle","year":"2019","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.33","article-title":"Supplementation of Influenza Split Vaccines With Conserved M2 Ectodomains Overcomes Strain Specificity and Provides Long-Term Cross Protection","volume":"22","author":"Kim","year":"2014","journal-title":"Mol Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/978-1-4939-3387-7_28","article-title":"Highly Effective Soluble and Bacteriophage T4 Nanoparticle Plague Vaccines Against Yersinia Pestis","volume":"1403","author":"Tao","year":"2016","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"eabh1547","DOI":"10.1126\/sciadv.abh1547","article-title":"A Universal Bacteriophage T4 Nanoparticle Platform to Design Multiplex SARS-CoV-2 Vaccine Candidates by CRISPR Engineering","volume":"7","author":"Zhu","year":"2021","journal-title":"Sci Adv"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22267","article-title":"Acceptable Levels of Endotoxin in Vaccine Formulations During Preclinical Research","volume":"100","author":"Brito","year":"2011","journal-title":"J Pharm Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.745625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T13:48:18Z","timestamp":1634132898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.745625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2021.745625"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.745625","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.06.14.448336","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"article-number":"745625"}}